Bharat Biotech’s Covaxin phase 3 trials efficacy data approved by SEC

Bharat Biotech phase 3 trials efficacy data has been approved by the Subject Expert Committee (SEC). As per CNBC TV18 reports, the phase 3 trials for the vaccine were conducted on around 25,800 subjects where Covaxin has shown 77.8 per cent efficacy according to the data submitted.

Over the weekend, phase 3 trials efficacy data results of the Covaxin vaccine have been submitted to the Drug Controller General of India by the Hyderabad based vaccine maker, as said on 21st June by a member of Centre’s topmost think tank NITI Aayog, Dr VK Paul.

As per the results published in The Lancet Infectious Disease journal, enhanced immune response without any serious side effects in the participants enrolled for the trials have been shown by the indigenously developed vaccine during its phase 1 trials.

By chemically treating novel COVID-19 samples to make them capable of reproduction, Covaxin is an inactivated vaccine developed by the process which leaves the viral proteins including the spike protein of the virus used to enter the human cells, intact.

As reported by Scroll, for emergency use listing of the COVID-19 vaccine candidate, on 23rd July Bharat Biotech is also expected to attend a pre-submission meeting with the World Health Organization (WHO) on the same. As per the report, facilitating easier International travel of Indian citizens who have been given the jab, an approval from the World Health Organization shall allow the vaccine maker to export its vaccine.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More